Investment & M&A transaction comps
Pharma Investment & M&A Transaction Comps
Explore investment and M&A transactions tagged pharma. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.
Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.
- Reviewed transactions
- 16
- With value data
- 7
- With revenue multiples
- 3
- Transaction years
- 2007–2026
Sortable transaction comps
Pharma transaction table
Rows with reported value
8 / 16
Acquisition EV, USD
USD 26B
Investment EV, USD
-
Median EV / revenue
5.3x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
16 shown of 16 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sofie Biosciences Control | 2026-10-05 | GE HealthCare | USD 945M Enterprise Value | 945 | - | - | United States | Confirmed 3 sources | ||
| ITM Isotope Technologies Munich SE Control (100%) | 2026-09-20 | Telix Pharmaceuticals Limited | USD 1.6B Enterprise Value | 1,650 | 6.0x | - | Germany | Confirmed 3 sources | ||
| Dersimelagon rights Control | 2026-08-18 | LEO Pharma | USD 435M Consideration | 435 | - | - | Denmark / Japan | Confirmed 3 sources | ||
| E-Pharma Trento Control (100%) | 2026-08-07 | Wise Equity | Undisclosed | Undisclosed | - | - | Italy | Confirmed 1 source | ||
| 2026-07-13 | Servier | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | |||
| 4E Therapeutics Control | 2026-06-16 | Eli Lilly and Company | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| XOMA Control | 2026-04-27 | Ligand | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| Tianjin TSKF Pharmaceutical Co., Ltd. Control (12%) | 2025-06-27 | Haleon plc | Undisclosed | Undisclosed | - | - | China | Confirmed 9 sources | ||
| Tianjin TSKF Pharmaceutical Co. Ltd (TSKF) Control (33%) | 2024-09-27 | Haleon | Undisclosed | Undisclosed | - | - | China | Estimated 10 sources | ||
| Aerie Pharmaceuticals, Inc. Control (100%) | 2022-08-22 | Alcon Research, Ltd. | USD 750M Enterprise Value | 750 | 4.4x | - | United States | Estimated 1 source | ||
| Biohaven Pharmaceutical Control | 2022-05-10 | Pfizer | USD 12B Consideration | 11,600 | - | 13.5x | United States | Confirmed 1 source | ||
| Flexion Therapeutics Control | 2021-10-11 | Pacira BioSciences | Undisclosed | Undisclosed | - | 11.0x | United States | Confirmed 1 source | ||
| GW Pharmaceuticals Control | 2021-02-03 | Jazz Pharmaceuticals | USD 7.2B | 7,200 | - | 12.9x | - | Confirmed 1 source | ||
| Celgene Control | 2019-01-03 | Bristol-Myers Squibb | Undisclosed Enterprise Value | Undisclosed | - | - | United States | Confirmed 2 sources | ||
| Sucampo Pharmaceuticals, Inc. Control | 2017-12-26 | Mallinckrodt | USD 1.2B | 1,200 | 4.6x | - | - | Confirmed 1 source | ||
| Adams Respiratory Therapeutics Inc. Control (100%) | 2007-12-11 | Reckitt Benckiser Group plc | USD 2.3B Consideration | 2,300 | 6.4x | 30.4x | United States | Confirmed 1 source |
Explore related tags
Continue to the full transaction history for each tag.
Explore buyers & investors
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.